RHY Stock Overview
Engages in developing and commercializing medical diagnostics technology in Australia and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rhythm Biosciences Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.063 |
52 Week High | AU$0.55 |
52 Week Low | AU$0.063 |
Beta | 2.64 |
1 Month Change | -15.54% |
3 Month Change | -37.50% |
1 Year Change | -84.57% |
3 Year Change | -93.21% |
5 Year Change | -64.29% |
Change since IPO | -81.06% |
Recent News & Updates
Recent updates
Shareholder Returns
RHY | AU Healthcare | AU Market | |
---|---|---|---|
7D | -5.3% | 4.3% | 0.1% |
1Y | -84.6% | -20.2% | 6.2% |
Return vs Industry: RHY underperformed the Australian Healthcare industry which returned -20.2% over the past year.
Return vs Market: RHY underperformed the Australian Market which returned 6.2% over the past year.
Price Volatility
RHY volatility | |
---|---|
RHY Average Weekly Movement | 6.9% |
Healthcare Industry Average Movement | 5.9% |
Market Average Movement | 8.4% |
10% most volatile stocks in AU Market | 15.9% |
10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: RHY's share price has been volatile over the past 3 months.
Volatility Over Time: RHY's weekly volatility has decreased from 15% to 7% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | n/a | n/a | www.rhythmbio.com |
Rhythm Biosciences Limited, engages in developing and commercializing medical diagnostics technology in Australia and internationally. It develops ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.
Rhythm Biosciences Limited Fundamentals Summary
RHY fundamental statistics | |
---|---|
Market cap | AU$15.91m |
Earnings (TTM) | -AU$8.63m |
Revenue (TTM) | AU$2.07m |
8.0x
P/S Ratio-1.9x
P/E RatioIs RHY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RHY income statement (TTM) | |
---|---|
Revenue | AU$2.07m |
Cost of Revenue | AU$2.04m |
Gross Profit | AU$27.30k |
Other Expenses | AU$8.66m |
Earnings | -AU$8.63m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.034 |
Gross Margin | 1.32% |
Net Profit Margin | -417.89% |
Debt/Equity Ratio | 0% |
How did RHY perform over the long term?
See historical performance and comparison